Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 January 2024 | Story EDZANI NEPHALELA | Photo ANJA AUCAMP
Dr Martin Laubscher
Dr Martin Laubscher’s thesis, crowned with the Andrew Murray-Desmond Tutu Prize, is testament to the university’s unwavering commitment to scholarly excellence.

In a historic triumph that reverberates over four decades since its inception, the UFS has clinched the coveted Andrew Murray Prize – now renamed the Andrew Murray-Desmond Tutu Prize – for the first time. Standing shoulder to shoulder with institutions such as the University of Pretoria (UP) and Stellenbosch University (SU), this achievement marks a significant milestone in the UFS’ journey.

At the heart of this accomplishment lies the profound contribution of Dr Martin Laubscher, distinguished Senior Lecturer specialising in Practical and Missional Theology in the Faculty of Theology and Religion. Dr Laubscher’s dedication and scholarly prowess culminated in the groundbreaking work titled Publieke teologie as profetiese teologie? (Public theology as prophetic theology), a revised edition of his doctoral thesis, which was originally crafted at Stellenbosch University in 2020, with a focus on the eminent Karl Barth.

Dr Laubscher received the Andrew Murray Prize for Theological Books in Afrikaans for his research and insightful analysis. The journey started when he realised, under the guidance of his study leader, Prof Dion Forster, that his script had the potential to be published in Afrikaans. Sun Media’s interest in publishing this work in Afrikaans, led to it being the first-ever published thesis in Afrikaans. Dr Laubscher recalls, “I was grateful and excited about Sun Media’s interest. The book emerged within a year, and during a celebratory launch Prof Forster suggested I submit it for the Andrew Murray Prize.”

Earlier this year, Dr Laubscher was excited to learn that he was being shortlisted for the prestigious award. Reflecting on the significant moment, he shares, “The elation I felt upon receiving the news was unparalleled. I was not only celebrating a personal triumph, but also etching my name as the first laureate from our faculty to secure this prestigious accolade.”

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept